Anthracyclines: cardiotoxicity and its prevention.
Authors:
- I J LewisILI J Lewis
Open Access
- 1 November 1994
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 71 (5) , 457-462
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.Heart, 1993
- Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients With Soft-Tissue Sarcomas: A Southwest Oncology Group StudyJNCI: Journal of the National Cancer Institute, 1991
- Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyEuropean Journal of Cancer and Clinical Oncology, 1989
- Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamicsAmerican Heart Journal, 1989
- Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacyEuropean Journal of Cancer and Clinical Oncology, 1989
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerNew England Journal of Medicine, 1988
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987
- Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiographyThe American Journal of Cardiology, 1986
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977
- Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemiaCancer, 1967